source
- Neurocrine's Prader-Willi drug Vykat XR linked to multiple deaths and serious side effectsA group of physicians and experts in Prader-Willi syndrome warned clinicians about safety concerns with Vykat XR, a drug approved by the FDA in March 2025 to reduce the intense hunger in patients w…
- Sentynl inks up to $475M licensing deal to commercialize Mereo’s alvelestat for rare lung diseaseSentynl Therapeutics, a subsidiary of Zydus Lifesciences, signed an agreement to obtain exclusive U.S. rights to market alvelestat, Mereo BioPharma’s investigational therapy for alpha-1 antitrypsin…